午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

返回ChemicalBook首頁(yè)>CAS數(shù)據(jù)庫(kù)列表>219311-44-1

219311-44-1

中文名稱 達(dá)布扎瓊
英文名稱 Dabuzalgron
CAS 219311-44-1
分子式 C12H16ClN3O3S
分子量 317.79
MOL 文件 219311-44-1.mol
更新日期 2023/12/27 09:22:16
219311-44-1 結(jié)構(gòu)式 219311-44-1 結(jié)構(gòu)式

基本信息

中文別名
達(dá)布扎瓊
N-[6-氯-3-[(4,5-二氫-1H-咪唑-2-基)甲氧基]-2-甲基苯基]甲磺酰胺
英文別名
Ro 115-1240
Dabuzalgron
N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methyl-phenyl]me thanesulfonamide
MethanesulfonaMide, N-[6-chloro-3-[(4,5-dihydro-1H-iMidazol-2-yl)Methoxy]-2-Methylphenyl]-

物理化學(xué)性質(zhì)

密度1.46
儲(chǔ)存條件-20°C儲(chǔ)存
溶解度DMSO: 26 mg/mL (81.82 mM)
形態(tài)Solid
顏色White to off-white

安全數(shù)據(jù)

危險(xiǎn)性符號(hào)(GHS)GHS hazard pictograms
GHS07
警示詞警告
危險(xiǎn)性描述H302-H315-H319-H335

常見問題列表

生物活性
Dabuzalgron (Ro 115-1240) 是一種口服活性的,選擇性的 α-1A 腎上腺素能受體激動(dòng)劑,動(dòng)物模型中,用于緩解尿失禁。Dabuzalgron 可通過維持線粒體功能來(lái)預(yù)防由阿霉素引起的心臟毒性。
靶點(diǎn)

α-1A adrenergic receptor

體外研究

Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an EC 50 of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron.
Dabuzalgron (10 μM; 4 hours) protects NRVMs from cell death due to Doxorubicin (DOX).
Activation of the α1A-AR with Dabuzalgron (10 μM; 4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage.

Western Blot Analysis

Cell Line: Neonatal rat ventricular myocytes (NRVMs)
Concentration: 0.1 μM, 1 μM, 10 μM and 100 μM
Incubation Time: 15 minutes
Result: Increased ERK phosphorylation in a dose-dependent fashion with an EC 50 of 4.8 μM.
體內(nèi)研究

Dabuzalgron (10 μg/kg; oral gavage; twice daily; for 7 days; C57Bl6J wild-type or α1A-AR knockout mice) treatment protects against DOX cardiotoxicity by activating the α1A-AR. Dabuzalgron protects against the reduction in transcripts related to mitochondrial function, up-regulates PGC1α, preserves ATP content, and reduces oxidative stress in the hearts of mice treated with DOX.

Animal Model: Male C57Bl6J wild-type (WT) or α1A-AR knockout (AKO) mice (8-12-week-old) injected with Doxorubicin (DOX)
Dosage: 10 μg/kg
Administration: Oral gavage; twice daily; for 7 days
Result: Preserved contractile function and reduced fibrosis after DOX administration. AKO mice treated with DOX had worse survival and more profoundly impaired contractile function than WT mice. Protected against the reduction in transcripts related to mitochondrial function, preserved ATP content, and reduced oxidative stress in the hearts of mice treated with DOX.
"219311-44-1" 相關(guān)產(chǎn)品信息
122-84-9 456-55-3 100-66-3 123-11-5 70-55-3 104-94-9 98-10-2 63-74-1 288-32-4 75-45-6